Vice President, CMC, Abcentra
Caitlin Prendes is a scientist, inventor, and biotech executive who builds what it takes to bring therapies to patients: the science, the technical capabilities, and the organizations behind them. Her experience spans development through commercialization, guided by the conviction that advancing science and investing in people go hand in hand.
As vice president of chemistry, manufacturing and controls (CMC) and technical operations at Abcentra, Prendes leads development, manufacturing, CMC regulatory affairs and quality. She shapes the company’s technical strategy to advance programs for patients whose needs remain underserved.
As an early employee at Synthekine, she built a multidisciplinary organization from the ground up, established internal development and analytical laboratories, and directed CMC strategy and manufacturing partnerships across a diverse biologics portfolio. At Boehringer Ingelheim, she led a team supporting late-stage and commercial biologics. At HCW Biologics, she established a development function and co-invented technology that she brought into clinical manufacturing. She began her career developing the purification process for the therapy now commercialized as ANKTIVA.
For Prendes, building a company means creating opportunities for people to grow. She mentors early-career scientists, helps scientists become leaders, and supports women in science and executive leadership. She brings the same commitment to developing people that she brings to developing therapies.
She holds an MBA from the University of California, Berkeley, Haas School of Business and a master’s degree from Johns Hopkins University.
Follow her on LinkedIn.